0001569340 2025-01-01 2025-03-31 0001569340 2026-05-13 0001569340 2025-03-31 0001569340 2024-12-31 0001569340 us-gaap:NonrelatedPartyMember 2025-03-31 0001569340 us-gaap:NonrelatedPartyMember 2024-12-31 0001569340 us-gaap:RelatedPartyMember 2025-03-31 0001569340 us-gaap:RelatedPartyMember 2024-12-31 0001569340 CLCS:SeriesAConvertiblePreferredStockMember 2025-03-31 0001569340 CLCS:SeriesAConvertiblePreferredStockMember 2024-12-31 0001569340 CLCS:SeriesBConvertiblePreferredStockMember 2025-03-31 0001569340 CLCS:SeriesBConvertiblePreferredStockMember 2024-12-31 0001569340 CLCS:SeriesCConvertiblePreferredStockMember 2025-03-31 0001569340 CLCS:SeriesCConvertiblePreferredStockMember 2024-12-31 0001569340 us-gaap:NonrelatedPartyMember CLCS:NotesPayableMember 2025-03-31 0001569340 us-gaap:NonrelatedPartyMember CLCS:NotesPayableMember 2024-12-31 0001569340 us-gaap:RelatedPartyMember CLCS:NotesPayableMember 2025-03-31 0001569340 us-gaap:RelatedPartyMember CLCS:NotesPayableMember 2024-12-31 0001569340 us-gaap:NonrelatedPartyMember us-gaap:ConvertibleNotesPayableMember 2025-03-31 0001569340 us-gaap:NonrelatedPartyMember us-gaap:ConvertibleNotesPayableMember 2024-12-31 0001569340 2024-01-01 2024-03-31 0001569340 us-gaap:NonrelatedPartyMember 2025-01-01 2025-03-31 0001569340 us-gaap:NonrelatedPartyMember 2024-01-01 2024-03-31 0001569340 us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0001569340 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0001569340 CLCS:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001569340 CLCS:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001569340 CLCS:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001569340 us-gaap:CommonStockMember 2024-12-31 0001569340 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001569340 us-gaap:RetainedEarningsMember 2024-12-31 0001569340 CLCS:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001569340 CLCS:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001569340 CLCS:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001569340 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001569340 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001569340 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001569340 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001569340 CLCS:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001569340 CLCS:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001569340 CLCS:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001569340 us-gaap:CommonStockMember 2025-03-31 0001569340 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001569340 us-gaap:RetainedEarningsMember 2025-03-31 0001569340 CLCS:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001569340 CLCS:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001569340 CLCS:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001569340 us-gaap:CommonStockMember 2023-12-31 0001569340 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001569340 us-gaap:RetainedEarningsMember 2023-12-31 0001569340 2023-12-31 0001569340 CLCS:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001569340 CLCS:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001569340 CLCS:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001569340 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001569340 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001569340 CLCS:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001569340 CLCS:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001569340 CLCS:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001569340 us-gaap:CommonStockMember 2024-03-31 0001569340 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001569340 us-gaap:RetainedEarningsMember 2024-03-31 0001569340 2024-03-31 0001569340 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001569340 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001569340 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001569340 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001569340 CLCS:OptionsMember 2025-01-01 2025-03-31 0001569340 CLCS:OptionsMember 2024-01-01 2024-03-31 0001569340 CLCS:NotesPayableMember 2025-03-31 0001569340 CLCS:NotesPayableMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:InvestorMember CLCS:SeriesBConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2025-04-01 2025-04-01 0001569340 us-gaap:InvestorMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-04-01 2025-04-01 0001569340 us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001569340 us-gaap:StockOptionMember 2024-01-01 2024-03-31 0001569340 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001569340 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001569340 CLCS:ConvertibleNotesMember 2025-01-01 2025-03-31 0001569340 CLCS:ConvertibleNotesMember 2024-01-01 2024-03-31 0001569340 us-gaap:ConvertiblePreferredStockMember 2025-01-01 2025-03-31 0001569340 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-03-31 0001569340 CLCS:WarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001569340 CLCS:AccruedCompensationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001569340 CLCS:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001569340 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001569340 CLCS:WarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-03-31 0001569340 CLCS:AccruedCompensationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-03-31 0001569340 CLCS:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-03-31 0001569340 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-03-31 0001569340 CLCS:WarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001569340 CLCS:AccruedCompensationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001569340 CLCS:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001569340 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001569340 CLCS:WarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001569340 CLCS:AccruedCompensationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001569340 CLCS:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001569340 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001569340 CLCS:WarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-01-01 2024-03-31 0001569340 CLCS:AccruedCompensationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-01-01 2024-03-31 0001569340 CLCS:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-01-01 2024-03-31 0001569340 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-01-01 2024-03-31 0001569340 CLCS:WarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001569340 CLCS:AccruedCompensationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001569340 CLCS:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001569340 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001569340 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-01-01 2025-03-31 0001569340 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-01-01 2025-03-31 0001569340 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-01-01 2024-03-31 0001569340 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-01-01 2024-03-31 0001569340 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2025-01-01 2025-03-31 0001569340 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2025-01-01 2025-03-31 0001569340 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-03-31 0001569340 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-03-31 0001569340 us-gaap:MeasurementInputPriceVolatilityMember 2025-01-01 2025-03-31 0001569340 us-gaap:MeasurementInputPriceVolatilityMember 2024-01-01 2024-03-31 0001569340 us-gaap:MeasurementInputExpectedDividendRateMember 2025-01-01 2025-03-31 0001569340 us-gaap:MeasurementInputExpectedDividendRateMember 2024-01-01 2024-03-31 0001569340 CLCS:ServiceProvidersMember 2025-01-01 2025-03-31 0001569340 CLCS:ServiceProvidersMember 2024-01-01 2024-12-31 0001569340 CLCS:OptionPricingMethodMember 2025-01-01 2025-03-31 0001569340 CLCS:OptionPricingMethodMember 2024-01-01 2024-12-31 0001569340 CLCS:ServiceProvidersMember 2025-03-31 0001569340 CLCS:ServiceProvidersMember 2024-12-31 0001569340 CLCS:NotesAndConvertibleNotesPayableMember 2025-03-31 0001569340 CLCS:NotesAndConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 CLCS:NotesAndConvertibleNotesPayableMember 2025-01-01 2025-03-31 0001569340 CLCS:NotesAndConvertibleNotesPayableMember 2024-01-01 2024-03-31 0001569340 CLCS:NotesPayableMember 2024-12-31 0001569340 us-gaap:InvestorMember 2025-03-31 0001569340 us-gaap:InvestorMember CLCS:NotesPayableMember 2025-01-01 2025-03-31 0001569340 us-gaap:InvestorMember CLCS:NotesPayableMember 2025-03-31 0001569340 us-gaap:InvestorMember CLCS:ConvertibleNotePayableMember us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember us-gaap:RelatedPartyMember 2025-03-31 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0001569340 CLCS:NoteholderMember us-gaap:ConvertibleNotesPayableMember CLCS:NoteAmendmentAgreementOneMember 2025-03-31 0001569340 CLCS:NoteholderMember us-gaap:ConvertibleNotesPayableMember CLCS:NoteAmendmentAgreementOneMember 2025-01-01 2025-03-31 0001569340 srt:MinimumMember CLCS:NoteholderMember us-gaap:ConvertibleNotesPayableMember CLCS:NoteAmendmentAgreementOneMember 2025-03-31 0001569340 CLCS:LenderMember us-gaap:ConvertibleNotesPayableMember CLCS:NoteAmendmentAgreementOneMember 2025-03-31 0001569340 us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember CLCS:NoteAmendmentAgreementOneMember 2025-03-31 0001569340 CLCS:NoteholderMember us-gaap:ConvertibleNotesPayableMember CLCS:NoteAmendmentAgreementTwoMember 2025-03-31 0001569340 CLCS:NoteholderMember us-gaap:ConvertibleNotesPayableMember CLCS:NoteAmendmentAgreementTwoMember 2025-01-01 2025-03-31 0001569340 srt:MinimumMember CLCS:NoteholderMember us-gaap:ConvertibleNotesPayableMember CLCS:NoteAmendmentAgreementTwoMember 2025-03-31 0001569340 CLCS:LenderMember us-gaap:ConvertibleNotesPayableMember CLCS:NoteAmendmentAgreementTwoMember 2025-03-31 0001569340 us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember CLCS:NoteAmendmentAgreementTwoMember 2025-03-31 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember 2025-01-01 2025-03-31 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember 2025-03-31 0001569340 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001569340 us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001569340 us-gaap:PreferredStockMember 2025-03-31 0001569340 us-gaap:PreferredStockMember 2024-12-31 0001569340 us-gaap:InvestorMember CLCS:SeriesBConvertiblePreferredStockMember 2025-01-01 2025-03-31 0001569340 us-gaap:InvestorMember CLCS:SeriesBConvertiblePreferredStockMember 2025-03-31 0001569340 us-gaap:InvestorMember CLCS:SeriesBConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001569340 us-gaap:InvestorMember us-gaap:CommonStockMember 2025-03-31 0001569340 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:WarrantMember CLCS:AdvisoryAgreementMember 2025-03-31 0001569340 us-gaap:WarrantMember CLCS:AdvisoryAgreementMember 2025-01-01 2025-03-31 0001569340 us-gaap:WarrantMember CLCS:WarrantAmendmentAgreementsMember 2025-03-31 0001569340 CLCS:WarrantAmendmentAgreementsMember 2025-01-01 2025-03-31 0001569340 us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001569340 CLCS:StockOptionsMember 2025-01-01 2025-03-31 0001569340 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001569340 CLCS:ConsultingServicesMember 2025-01-01 2025-03-31 0001569340 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001569340 CLCS:ConsultingServicesMember 2024-01-01 2024-03-31 0001569340 CLCS:FormerDirectorMember 2025-03-31 0001569340 CLCS:FormerDirectorMember 2024-12-31 0001569340 CLCS:YedaResearchAndLicenseAgreementMember 2025-01-01 2025-03-31 0001569340 CLCS:YedaResearchAndLicenseAgreementMember 2024-01-01 2024-03-31 0001569340 CLCS:YedaResearchAndLicenseAgreementMember 2025-03-31 0001569340 CLCS:YedaResearchAndLicenseAgreementMember 2024-12-31 0001569340 CLCS:MDAndersonAgreementsMember 2025-01-01 2025-03-31 0001569340 CLCS:MDAndersonAgreementsMember 2024-01-01 2024-03-31 0001569340 CLCS:MDAndersonAgreementsMember 2025-02-28 2025-05-27 0001569340 CLCS:MDAndersonAgreementsMember 2025-03-31 0001569340 CLCS:MDAndersonAgreementsMember 2024-12-31 0001569340 us-gaap:InvestorMember us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 CLCS:IssuanceOfCommonStockMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 CLCS:IssuanceOfCommonStockMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 CLCS:IssuanceOfCommonStockMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:DeferredProfitSharingMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:RelatedPartyMember us-gaap:SubsequentEventMember 2025-04-01 2025-11-15 0001569340 us-gaap:InvestorMember us-gaap:RelatedPartyMember us-gaap:SubsequentEventMember 2025-11-15 0001569340 us-gaap:InvestorMember CLCS:IssuanceOfNotesPayableMember us-gaap:SubsequentEventMember 2026-11-15 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember CLCS:IssuanceOfNotesPayableMember 2025-11-15 0001569340 us-gaap:RelatedPartyMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2025-04-01 2025-11-16 0001569340 us-gaap:InvestorMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2025-11-16 0001569340 us-gaap:RelatedPartyMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2025-11-16 0001569340 us-gaap:InvestorMember CLCS:IssuanceOfNotesPayableMember us-gaap:SubsequentEventMember 2025-11-16 0001569340 us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember CLCS:IssuanceOfNotesPayableMember 2025-11-16 0001569340 us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:SubsequentEventMember CLCS:IssuanceOfNotesPayableMember 2026-05-11 0001569340 us-gaap:PurchaseCommitmentMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:SubsequentEventMember 2025-04-01 2026-01-07 0001569340 CLCS:IssuanceOfNotesPayableMember us-gaap:SubsequentEventMember 2025-04-01 2026-01-07 0001569340 us-gaap:SubsequentEventMember CLCS:NoteAmendmentAgreementMember 2026-01-07 0001569340 us-gaap:InvestorMember CLCS:IssuanceOfNotesPayableMember us-gaap:SubsequentEventMember 2026-01-07 0001569340 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-04-01 2026-01-07 0001569340 us-gaap:SubsequentEventMember CLCS:IssuanceOfNotesPayableMember 2025-04-01 2025-11-20 0001569340 CLCS:IssuanceOfNotesPayableMember us-gaap:SubsequentEventMember 2025-04-01 2025-11-20 0001569340 us-gaap:InvestorMember us-gaap:SubsequentEventMember CLCS:NoteAmendmentAgreementMember 2025-11-20 0001569340 us-gaap:InvestorMember CLCS:IssuanceOfNotesPayableMember us-gaap:SubsequentEventMember 2025-11-20 0001569340 us-gaap:InvestorMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:InvestorMember CLCS:IssuanceOfNotesPayableMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:InvestorMember CLCS:IssuanceOfNotesPayableMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:InvestorMember CLCS:PrivatePlacementConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:ConvertibleNotesPayableMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 CLCS:NotesPayableMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:SubsequentEventMember 2026-05-11 0001569340 CLCS:IssuanceOfNotesPayableMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2026-03-06 0001569340 us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2025-04-01 2026-03-06 0001569340 us-gaap:RelatedPartyMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2026-03-06 0001569340 us-gaap:RelatedPartyMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2025-04-01 2026-03-06 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:SubsequentEventMember 2025-07-31 0001569340 us-gaap:SubsequentEventMember CLCS:NoteAmendmentAgreementMember 2025-07-31 0001569340 CLCS:NotesPayableMember 2025-07-31 0001569340 us-gaap:InvestorMember us-gaap:SubsequentEventMember 2025-12-31 0001569340 CLCS:NotesPayableMember us-gaap:SubsequentEventMember 2025-12-31 0001569340 srt:ScenarioForecastMember CLCS:NotesPayableMember 2026-06-30 0001569340 CLCS:LenderMember us-gaap:SubsequentEventMember CLCS:NoteAmendmentAgreementMember 2026-05-11 0001569340 us-gaap:InvestorMember us-gaap:SubsequentEventMember CLCS:NoteAmendmentAgreementMember 2025-07-31 0001569340 CLCS:NotesPayableMember us-gaap:SubsequentEventMember CLCS:NoteAmendmentAgreementMember 2025-07-31 0001569340 us-gaap:InvestorMember us-gaap:SubsequentEventMember CLCS:NoteAmendmentAgreementMember 2025-12-31 0001569340 srt:ScenarioForecastMember CLCS:NotesPayableMember CLCS:NoteAmendmentAgreementMember 2026-06-30 0001569340 CLCS:LenderMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 CLCS:HolderMember us-gaap:SubsequentEventMember CLCS:NoteAmendmentAgreementMember 2025-12-31 0001569340 us-gaap:InvestorMember us-gaap:WarrantMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:WarrantMember us-gaap:SubsequentEventMember CLCS:AdvisoryAgreementMember 2026-05-11 0001569340 us-gaap:WarrantMember us-gaap:SubsequentEventMember CLCS:AdvisoryAgreementMember 2025-04-01 2026-05-11 0001569340 CLCS:SeriesAConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 CLCS:SeriesAConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 CLCS:SeriesCConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 CLCS:SeriesCConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2025-04-01 2026-05-11 0001569340 us-gaap:NotesPayableOtherPayablesMember us-gaap:WarrantMember us-gaap:SubsequentEventMember 2026-05-11 0001569340 us-gaap:SubsequentEventMember CLCS:IssuanceOfNotesPayableMember 2026-01-07 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2025-07-31 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember 2025-07-31 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2025-12-31 0001569340 srt:ScenarioForecastMember us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember 2026-06-30 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember CLCS:NoteAmendmentAgreementMember 2025-07-31 0001569340 us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember CLCS:NoteAmendmentAgreementMember 2025-12-31 0001569340 srt:ScenarioForecastMember us-gaap:InvestorMember us-gaap:ConvertibleNotesPayableMember CLCS:NoteAmendmentAgreementMember 2026-06-30 0001569340 CLCS:HolderMember us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember CLCS:NoteAmendmentAgreementMember 2025-12-31 iso4217:USD shares iso4217:USD shares pure CLCS:Segments false --12-31 Q1 0001569340 10-Q true 2025-03-31 2025 false 000-55413 Cell Source, Inc. NV 32-0379665 57 West 57th Street Suite 400 New York NY 10019 (646) 416-7896 Yes Yes Non-accelerated Filer true false false 67945856 0.001 1240 74631 80375 160750 209427 50000 1404 1119 292446 286500 1929223 1888729 1441697 1115501 217000 202500 217000 202500 1168356 973436 2193741 1994418 2193741 1994418 1092413 1067777 0 1479 1177343 1175864 34265 0 795345 443750 795345 443750 19373 8500 966707 986500 7561708 7561708 7561708 7561708 89118 86972 131792 129113 131792 129113 543997 479844 151228 101659 151228 101659 314985 314985 194375 194375 100000 100000 359453 7205 20428481 18824336 0.001 0.001 10000000 10000000 1350000 1350000 1342195 1342195 1342195 1342195 10289854 10066463 1342 1342 2000000 2000000 266794 266794 266794 266794 2057447 2008108 267 267 1000000 1000000 537482 537482 537482 537482 4110634 4031115 537 537 0.001 0.001 200000000 200000000 45038244 45038244 45038244 45038244 45038 45038 27478662 27595010 -47661881 -46180030 -20136035 -18537836 292446 286500 500683 341713 14500 14500 14500 14500 483404 781916 998587 1138129 -998587 -1138129 216923 64804 210314 158010 210314 158010 6686 4954 79951 1002 79951 1002 23068 39621 7542 51872 7542 51872 -483264 -137277 -1481851 -1275406 352248 326665 -1834099 -1602071 -0.04 -0.04 -0.04 -0.04 45038244 45038244 40507352 40507352 1342195 1342 266794 267 537482 537 45038244 45038 27595010 -46180030 -18537836 352248 352248 17200 17200 92197 92197 21994 21994 3909 3909 100600 100600 1000000 1000 259000 260000 -1481851 -1481851 1342195 1342 266794 267 537482 537 45038244 45038 27478662 -47661881 -20136035 1342195 1342 106668 107 537482 537 39830802 39831 26014028 -41667388 -15611543 1342195 1342 106668 107 537482 537 39830802 39831 26014028 -41667388 -15611543 13333 13 6546 6 104891 104910 13333 13 6546 6 104891 104910 326665 326665 180000 180 44820 45000 3333 3 19897 19900 2000 2 518 520 29141 29141 1000000 1000 259000 260000 -1275406 -1275406 1342195 1342 110001 110 550815 550 41019348 41019 26145630 -42942794 -16754143 1342195 1342 110001 110 550815 550 41019348 41019 26145630 -42942794 -16754143 -1481851 -1275406 6686 4954 79951 1002 79951 1002 30610 91493 32992 11378 17200 262351 3875 26544 100600 100600 -80375 -80377 209427 285 -10025 40494 415350 326196 96273 14500 14500 14500 14500 194920 32738 199323 178685 199323 178685 24670 58870 -600391 -173852 25000 25000 50000 150000 56000 6000 327000 146672 75000 20000 527000 151672 -73391 -22180 74631 22203 1240 23 6666 -45000 55356 -352248 -326665 104910 2205 3200 801 1900 57803 <p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zGcJO5RIsJK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - <span id="xdx_822_zsAEqjbOXTc9">Business Organization, Nature of Operations, Risks and Uncertainties and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization and Operations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell Source, Inc. (“Cell Source”, “CSI” or the “Company”) is a Nevada corporation formed on June 6, 2012 that is the parent company of Cell Source Limited (“CSL”), a wholly owned subsidiary which was founded in Israel in 2011 in order to commercialize a suite of inventions relating to certain cancer treatments. The Company is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The Company’s lead prospective product is its patented Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. CSL’s Veto Cell immune system management technology is based on technologies patented, owned, and licensed to CSL by Yeda Research and Development Company Limited, an Israeli corporation (“Yeda”) (see Note 8, Commitments and Contingencies). The Company’s target indications include: lymphoma, leukemia and multiple myeloma through the facilitation of safer and more accessible stem cell (e.g. bone marrow) transplantation acceptance, treatment of end stage kidney disease and other non-malignant organ diseases through improved organ transplantation (broadened donor pool, reduced dependence on post-transplant anti-rejection therapy) and ultimately treating a variety of cancers and non-malignant diseases. The Company’s current research and development activities are primarily conducted through sponsored research agreements with The University of Texas MD Anderson Cancer Center (see Note 8, <i>Commitments and Contingencies</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks and Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2022, Russian military forces invaded Ukraine, and the length, impact, and outcome of the ongoing war in Ukraine is highly unpredictable. On October 7, 2023, Hamas terrorists infiltrated Israel’s border with the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas has also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks have resulted in extensive deaths, injuries and kidnapping. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Although there is currently a cease fire in the Israel-Hamas conflict, no assurance can be given that the cease fire will continue. On February 28, 2026, United States and Israeli forces conducted a series of attacks in Iran, and Iran responded by launching retaliatory attacks on Israel and United States military bases in the Middle East. The intensity and duration of the United States/Israel war against Iran is difficult to predict. As a result of the Russia-Ukraine, Israel-Hamas and United States/Israel-Iran wars and other geopolitical and macroeconomic events, the global credit and financial markets have experienced volatility and disruptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2025 and through the date of this filing, the Company considered the impact of these wars and other geopolitical and macroeconomic events on its business and operational assumptions and estimates and determined there were no material adverse impacts on the Company’s consolidated results of operations and financial position.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial position of the Company as of March 31, 2025 and the condensed consolidated results of its operations and cash flows for the three months ended March 31, 2025 and 2024. The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the operating results for the full year ending December 31, 2025 or any other period. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2024 and for the year then ended which were included in the Company’s Annual Report on Form 10-K that was filed with the Securities and Exchange Commission (“SEC”) on April 6, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80F_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zaqNuyOF8Ndh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - <span id="xdx_829_zxz3YtdKBfY4">Going Concern and Management Plans</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company did not generate any revenues, had a net loss of approximately $<span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20250101__20250331_zvPEHvvhgZSb" title="Net loss">1,482,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and used cash in operations of approximately $<span id="xdx_900_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3d_di_c20250101__20250331_zaQHHPjyCdZ8" title="Net cash provided by used in operating activities">600,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. As of March 31, 2025, the Company had a working capital deficiency of approximately $<span id="xdx_907_eus-gaap--StockholdersEquity_iNI_pn3d_di_c20250331_z3tPB1J93cMa" title="Working capital deficiency">20,136,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and an accumulated deficit of approximately $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3d_di_c20250331_zvcELfzxZE" title="Accumulated deficit">47,662,000</span>. As of March 31, 2025 and through the date of this filing, notes payable with principal amounts totaling approximately $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20250331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zFuptCposqO2" title="Notes payable, principal amount">6,328,000</span> and $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20260511__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0Ps98slRGFg" title="Notes payable, principal amount">11,116,000</span>, respectively, were past due. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the date these financial statements are issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is currently funding its operations on a month-to-month basis. While there can be no assurance that it will be successful, the Company is in active negotiations to raise additional capital. The Company’s primary sources of operating funds since inception have been equity and debt financings. Management’s plans include continued efforts to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, if the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. Subsequent to March 31, 2025 and as more fully described in Note 10, <i>Subsequent Events</i>, the Company received aggregate proceeds of approximately $<span id="xdx_902_eus-gaap--ProceedsFromNotesPayable_c20250401__20250401__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z8diHhlSy71b" title="Proceeds from notes payable">2,839,000</span> from the issuance of notes payable, $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250401__20250401__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzJDQZKe3XAd" title="Proceeds from issuance of convertible preferred stock">310,000</span> from the issuance of Series B Convertible Preferred Stock and $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250401__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv7EJ4Q4sBDd" title="Proceeds from issuance of common stock">100,000</span> from the issuance of Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -1482000 -600000 -20136000 -47662000 6328000 11116000 2839000 310000 100000 <p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zw2OT2jJ86wk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 - <span id="xdx_822_zXTG9FOxs0Ta">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no material changes to the Company’s significant accounting policies included in the Annual Report on Form 10-K for the year ended December 31, 2024, except as disclosed herein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_849_ecustom--ReclassificationsPolicyTextBlock_zX9sXyX30zkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zwcpMESi62sh">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts in the condensed consolidated financial statements and accompanying notes have been reclassified to conform to the current year presentation. These reclassifications had no effect on previously reported net loss, total assets, total liabilities, shareholders’ equity, or cash flows from operations. Management has evaluated these reclassifications and determined that they are <i>not</i> material, individually or in the aggregate, to the condensed consolidated financial statements taken as a whole.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zALQK32300S" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zaL2FogV9Kvh">Loss Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share includes the dilution that would occur upon the exercise or conversion of all dilutive securities into common stock using the “treasury stock” and/or “if converted” methods, as applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlQkr2q5J7F9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The common stock equivalents associated with the following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zjl7OqFhTdJi" style="display: none">Schedule of Weighted Average Dilutive Common Shares Anti-dilutive</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zAFjk8VXeVb3" style="width: 16%; text-align: right" title="Weighted average dilutive common shares,Options">11,457,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zp79Mf649o38" style="width: 16%; text-align: right" title="Weighted average dilutive common shares,Options">6,932,004</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5gNDP7OV6q8" style="text-align: right" title="Weighted average dilutive common shares, warrants">22,287,545</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zwoK3VWghB8a" style="text-align: right" title="Weighted average dilutive common shares, warrants">15,693,445</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes [1]</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_fWzFd_zXHcTjtcGAH2" style="text-align: right" title="Weighted average dilutive common shares, convertible notes">14,655,067</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_fWzFd_z4ghK6q8KFq5" style="text-align: right" title="Weighted average dilutive common shares, convertible notes">13,656,427</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zhxd17ai6GCa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average dilutive common shares, convertible preferred stock">21,464,713</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zMUc0klOlQK2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average dilutive common shares, convertible preferred stock">20,030,110</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331_zwiUbz0fRjji" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">69,864,329</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331_zfXQkZjeukr3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">56,311,986</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F08_zFSwLozGGd8k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[1]</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zj5bzj8vLLuh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes are assumed to be converted at the rate of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdlaWdodGVkIEF2ZXJhZ2UgRGlsdXRpdmUgQ29tbW9uIFNoYXJlcyBBbnRpLWRpbHV0aXZlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250331_zxgLgrv94xI2" title="Debt instrument convertible conversion price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdlaWdodGVkIEF2ZXJhZ2UgRGlsdXRpdmUgQ29tbW9uIFNoYXJlcyBBbnRpLWRpbHV0aXZlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240331_zlxHXr9N0z59" title="Debt instrument convertible conversion price">0.75</span></span> per common share, which is the conversion price as of March 31, 2025 and 2024. However, such conversion rates are subject to adjustment under certain circumstances, such as stock splits and stock dividends, which may result in the issuance of common shares greater than the amount indicated.</span></td></tr> </table> <p id="xdx_8A3_zzKkHADUjWy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zkYrcFABuMx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zHytXULAZME1">Recently Adopted Accounting Standards</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024 with early adoption permitted. The Company adopted ASU No. 2023-09 as of January 1, 2025 on a prospective basis and its adoption did not have a material impact on the Company’s condensed consolidated financial statements.</span></p> <p id="xdx_85A_z7EqIQIMtGVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_849_ecustom--ReclassificationsPolicyTextBlock_zX9sXyX30zkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zwcpMESi62sh">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts in the condensed consolidated financial statements and accompanying notes have been reclassified to conform to the current year presentation. These reclassifications had no effect on previously reported net loss, total assets, total liabilities, shareholders’ equity, or cash flows from operations. Management has evaluated these reclassifications and determined that they are <i>not</i> material, individually or in the aggregate, to the condensed consolidated financial statements taken as a whole.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zALQK32300S" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zaL2FogV9Kvh">Loss Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share includes the dilution that would occur upon the exercise or conversion of all dilutive securities into common stock using the “treasury stock” and/or “if converted” methods, as applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlQkr2q5J7F9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The common stock equivalents associated with the following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zjl7OqFhTdJi" style="display: none">Schedule of Weighted Average Dilutive Common Shares Anti-dilutive</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zAFjk8VXeVb3" style="width: 16%; text-align: right" title="Weighted average dilutive common shares,Options">11,457,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zp79Mf649o38" style="width: 16%; text-align: right" title="Weighted average dilutive common shares,Options">6,932,004</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5gNDP7OV6q8" style="text-align: right" title="Weighted average dilutive common shares, warrants">22,287,545</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zwoK3VWghB8a" style="text-align: right" title="Weighted average dilutive common shares, warrants">15,693,445</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes [1]</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_fWzFd_zXHcTjtcGAH2" style="text-align: right" title="Weighted average dilutive common shares, convertible notes">14,655,067</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_fWzFd_z4ghK6q8KFq5" style="text-align: right" title="Weighted average dilutive common shares, convertible notes">13,656,427</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zhxd17ai6GCa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average dilutive common shares, convertible preferred stock">21,464,713</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zMUc0klOlQK2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average dilutive common shares, convertible preferred stock">20,030,110</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331_zwiUbz0fRjji" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">69,864,329</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331_zfXQkZjeukr3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">56,311,986</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F08_zFSwLozGGd8k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[1]</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zj5bzj8vLLuh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes are assumed to be converted at the rate of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdlaWdodGVkIEF2ZXJhZ2UgRGlsdXRpdmUgQ29tbW9uIFNoYXJlcyBBbnRpLWRpbHV0aXZlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250331_zxgLgrv94xI2" title="Debt instrument convertible conversion price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdlaWdodGVkIEF2ZXJhZ2UgRGlsdXRpdmUgQ29tbW9uIFNoYXJlcyBBbnRpLWRpbHV0aXZlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240331_zlxHXr9N0z59" title="Debt instrument convertible conversion price">0.75</span></span> per common share, which is the conversion price as of March 31, 2025 and 2024. However, such conversion rates are subject to adjustment under certain circumstances, such as stock splits and stock dividends, which may result in the issuance of common shares greater than the amount indicated.</span></td></tr> </table> <p id="xdx_8A3_zzKkHADUjWy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zlQkr2q5J7F9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The common stock equivalents associated with the following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zjl7OqFhTdJi" style="display: none">Schedule of Weighted Average Dilutive Common Shares Anti-dilutive</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zAFjk8VXeVb3" style="width: 16%; text-align: right" title="Weighted average dilutive common shares,Options">11,457,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zp79Mf649o38" style="width: 16%; text-align: right" title="Weighted average dilutive common shares,Options">6,932,004</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5gNDP7OV6q8" style="text-align: right" title="Weighted average dilutive common shares, warrants">22,287,545</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zwoK3VWghB8a" style="text-align: right" title="Weighted average dilutive common shares, warrants">15,693,445</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes [1]</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_fWzFd_zXHcTjtcGAH2" style="text-align: right" title="Weighted average dilutive common shares, convertible notes">14,655,067</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_fWzFd_z4ghK6q8KFq5" style="text-align: right" title="Weighted average dilutive common shares, convertible notes">13,656,427</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zhxd17ai6GCa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average dilutive common shares, convertible preferred stock">21,464,713</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zMUc0klOlQK2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average dilutive common shares, convertible preferred stock">20,030,110</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250331_zwiUbz0fRjji" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">69,864,329</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331_zfXQkZjeukr3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">56,311,986</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F08_zFSwLozGGd8k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[1]</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zj5bzj8vLLuh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes are assumed to be converted at the rate of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdlaWdodGVkIEF2ZXJhZ2UgRGlsdXRpdmUgQ29tbW9uIFNoYXJlcyBBbnRpLWRpbHV0aXZlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250331_zxgLgrv94xI2" title="Debt instrument convertible conversion price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdlaWdodGVkIEF2ZXJhZ2UgRGlsdXRpdmUgQ29tbW9uIFNoYXJlcyBBbnRpLWRpbHV0aXZlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240331_zlxHXr9N0z59" title="Debt instrument convertible conversion price">0.75</span></span> per common share, which is the conversion price as of March 31, 2025 and 2024. However, such conversion rates are subject to adjustment under certain circumstances, such as stock splits and stock dividends, which may result in the issuance of common shares greater than the amount indicated.</span></td></tr> </table> 11457004 6932004 22287545 15693445 14655067 13656427 21464713 20030110 69864329 56311986 0.75 0.75 <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zkYrcFABuMx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zHytXULAZME1">Recently Adopted Accounting Standards</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024 with early adoption permitted. The Company adopted ASU No. 2023-09 as of January 1, 2025 on a prospective basis and its adoption did not have a material impact on the Company’s condensed consolidated financial statements.</span></p> <p id="xdx_805_eus-gaap--FairValueDisclosuresTextBlock_zQ6xIY0ZRGZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 - <span id="xdx_827_zDhkOsh0HXG4">Fair Value</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zaifsBA5Cbjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of the changes in fair value, including net transfers in and/or out, of all Level 3 liabilities measured at fair value on a recurring basis using unobservable inputs during the three months ended March 31, 2025 and 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zGxO1uEcx9T" style="display: none">Schedule of Changes in Fair Value of Liabilities Measured at Fair Value on a Recurring Basis</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Warrant</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accrued</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivative</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Compensation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; font-weight: bold">Balance - January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zAElJmIHykqi" style="width: 12%; text-align: right" title="Beginning balance">216,085</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkK7PUBlWB6d" style="width: 12%; text-align: right" title="Beginning balance">37,348</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLOjZonmzq1e" style="width: 12%; text-align: right" title="Beginning balance">581,503</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20250101__20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zahiP621zCd7" style="width: 12%; text-align: right" title="Beginning balance">834,936</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Issuance of warrants and conversion option</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvuLQTjxq1W8" style="text-align: right" title="Issuance of warrants and conversion option">7,760</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8sP7UioGFL5" style="text-align: right" title="Issuance of warrants and conversion option"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMViFmtUTon" style="text-align: right" title="Issuance of warrants and conversion option">141,397</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20250101__20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zjIKTSdiUHca" style="text-align: right" title="Issuance of warrants and conversion option">144,723</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziIMoG7Th1Aa" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(2,935</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoYJVmtw7uhl" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(34</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8BjyqMUc0d7" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(27,675</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20250101__20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFgFaayJr3Na" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(28,889</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance - March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTZKBVENqcgd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">220,910</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zfPoQaYgUuQ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">37,314</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoRVA8PcQgx1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">695,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20250101__20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znhldck8Dt0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">950,770</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Warrant</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accrued</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivative</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Compensation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; font-weight: bold">Balance - January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zyNhL49P5fEf" style="width: 12%; text-align: right" title="Beginning balance">356,510</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvWE8iinoupg" style="width: 12%; text-align: right" title="Beginning balance">97,102</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziDwn3fOsDod" style="width: 12%; text-align: right" title="Beginning balance">33,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zL5s0aOjz5v1" style="width: 12%; text-align: right" title="Beginning balance">486,612</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accrual of warrant obligation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zhqiwhizuz3h" style="text-align: right" title="Accrual of warrant obligation">6,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIxb1BzOkyai" style="text-align: right" title="Accrual of warrant obligation"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFCN6OjzMbKa" style="text-align: right" title="Accrual of warrant obligation"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTcoBqjH8xS1" style="text-align: right" title="Accrual of warrant obligation">6,666</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Issuance of warrants and conversion option</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z1RWheuspwge" style="text-align: right" title="Issuance of warrants and conversion option">11,377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zSMPMeUnwOig" style="text-align: right" title="Issuance of warrants and conversion option"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC95RdqeCg33" style="text-align: right" title="Issuance of warrants and conversion option">5,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdH7YvkrYTKi" style="text-align: right" title="Issuance of warrants and conversion option">16,477</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Common stock issued in satisfaction of accrued compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCommonStockIssuedInSatisfactionOfAccruedCompensation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZZv9NyhMCh5" style="text-align: right" title="Common stock issued in satisfaction of accrued compensation"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCommonStockIssuedInSatisfactionOfAccruedCompensation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrEsXQOdWRwj" style="text-align: right" title="Common stock issued in satisfaction of accrued compensation">(45,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCommonStockIssuedInSatisfactionOfAccruedCompensation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVB5XlsQBRZ3" style="text-align: right" title="Common stock issued in satisfaction of accrued compensation"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCommonStockIssuedInSatisfactionOfAccruedCompensation_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8JLiVHI87Di" style="text-align: right" title="Common stock issued in satisfaction of accrued compensation">(45,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNeXjwy03AO8" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(85,693</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z3GvBZTKEcO5" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(766</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zsFeoMibl4tf" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(5,800</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ztJiCflCbcke" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(92,259</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance - March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCKCSu9EMWvb" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">288,860</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zskyx4ty9ZKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">51,336</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVBPpr0MpFh2" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">32,300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7WmBEYOtXFb" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">372,496</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zAY0gw5vwllh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The Company’s Level 3 liabilities shown in the above table consist of warrants with “down-round protection”, as the Company is unable to determine if it will have sufficient authorized common stock to settle such arrangements, warrants deemed to be derivative liabilities according to the Company’s sequencing policy in accordance with ASC 815-40-35-12, the embedded conversion options within its convertible notes payable, the fair value of the Company’s obligation to issue penalty warrants (which is classified within warrant liabilities and warrant liabilities – related party on the condensed consolidated balance sheets), and an accrued obligation to issue common stock (which is a component of accrued compensation).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zKR9ZOHBBBTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In applying the Black-Scholes option pricing model utilized in the valuation of Level 3 liabilities, the Company used the following approximate assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zeXgMVUp3XT" style="display: none">Schedule of Assumptions Used for Valuation of Level 3 Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zsWZO5KiAnji" title="Derivative liabilities , Risk-free interest rate">3.89</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zyZZ1wln30ka" title="Derivative liabilities , Risk-free interest rate">4.35</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zKZeCZXfkVy6" title="Derivative liabilities , Risk-free interest rate">3.84</span>% - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zJ3vOfEfJxw" title="Derivative liabilities , Risk-free interest rate">4.35</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zf43XxFj7TA7" title="Derivative liability, Expected term (years)">2.62</span> - <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zxj1NBib9WZc" title="Derivative liability, Expected term (years)">10.00</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zkJTvdu0dhC4" title="Derivative liability, Expected term (years)">3.58</span> - <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zf8wvajBtXp4" title="Derivative liability, Expected term (years)">5.00</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zJSH2cJYmpf" title="Derivative liability, Expected volatility">70</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zCkMG5kh2Fm3" title="Derivative liability, Expected volatility">65</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zCI7VtzQ5ebh" title="Derivative liability, Expected dividends">0.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zp7MQ0SAFmn9" title="Derivative liability, Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_8A2_zfUUG2Wa8mal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected term used is the contractual life of the instrument being valued. Since the Company’s stock has not been publicly traded for a sufficiently long period of time or with significant volume, the Company is utilizing an expected volatility based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2025 and December 31, 2024, the Company had an obligation to issue <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20250331__srt--TitleOfIndividualAxis__custom--ServiceProvidersMember_z2Web8RLSeU6" title="Obilgation to issue to service providers, shares"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ServiceProvidersMember_z19Mao2fOEs5" title="Obilgation to issue to service providers, shares">183,095</span></span> shares of common stock to service providers that had a fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250331__srt--TitleOfIndividualAxis__custom--ServiceProvidersMember_zDsoBtfmruW5" title="Obilgation to issue to service providers, value"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ServiceProvidersMember_zyCpHbpfQXaf" title="Obilgation to issue to service providers, value">34,788</span></span>, which was a component of accrued compensation in the condensed consolidated balance sheets. The fair value of the common stock underlying this obligation has a per share value of $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331__us-gaap--PlanNameAxis__custom--OptionPricingMethodMember_z7DM1XSe8D11" title="Common stock fair value per share"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--OptionPricingMethodMember_zNXYN29bsnqa" title="Common stock fair value per share">0.19</span></span> as of March 31, 2025 and December 31, 2024. Furthermore, as of March 31, 2025 and December 31, 2024, the Company has an obligation to issue warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__srt--TitleOfIndividualAxis__custom--ServiceProvidersMember_zifbw2494Y1c" title="Warrants to purchase shares"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__srt--TitleOfIndividualAxis__custom--ServiceProvidersMember_zFi1W52HJk2f" title="Warrants to purchase shares">42,930</span></span> shares of the Company’s common stock to service providers that had a fair value of $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250331__srt--TitleOfIndividualAxis__custom--ServiceProvidersMember_znCmqcXAvTl" title="Fair value of warrants issued">2,526</span> and $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__srt--TitleOfIndividualAxis__custom--ServiceProvidersMember_zEoIjFaEOEig" title="Fair value of warrants issued">2,560</span>, respectively, which was a component of accrued compensation in the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 5, <i>Notes Payable </i>and Note 6, <i>Stockholders’ Deficiency </i>for additional details associated with the issuances of common stock, warrants and embedded conversion options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zaifsBA5Cbjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of the changes in fair value, including net transfers in and/or out, of all Level 3 liabilities measured at fair value on a recurring basis using unobservable inputs during the three months ended March 31, 2025 and 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zGxO1uEcx9T" style="display: none">Schedule of Changes in Fair Value of Liabilities Measured at Fair Value on a Recurring Basis</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Warrant</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accrued</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivative</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Compensation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; font-weight: bold">Balance - January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zAElJmIHykqi" style="width: 12%; text-align: right" title="Beginning balance">216,085</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkK7PUBlWB6d" style="width: 12%; text-align: right" title="Beginning balance">37,348</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLOjZonmzq1e" style="width: 12%; text-align: right" title="Beginning balance">581,503</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20250101__20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zahiP621zCd7" style="width: 12%; text-align: right" title="Beginning balance">834,936</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Issuance of warrants and conversion option</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvuLQTjxq1W8" style="text-align: right" title="Issuance of warrants and conversion option">7,760</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8sP7UioGFL5" style="text-align: right" title="Issuance of warrants and conversion option"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zMViFmtUTon" style="text-align: right" title="Issuance of warrants and conversion option">141,397</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20250101__20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zjIKTSdiUHca" style="text-align: right" title="Issuance of warrants and conversion option">144,723</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziIMoG7Th1Aa" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(2,935</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoYJVmtw7uhl" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(34</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8BjyqMUc0d7" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(27,675</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20250101__20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFgFaayJr3Na" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(28,889</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance - March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTZKBVENqcgd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">220,910</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zfPoQaYgUuQ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">37,314</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20250101__20250331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoRVA8PcQgx1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">695,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20250101__20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znhldck8Dt0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">950,770</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Warrant</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accrued</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivative</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Compensation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; font-weight: bold">Balance - January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zyNhL49P5fEf" style="width: 12%; text-align: right" title="Beginning balance">356,510</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvWE8iinoupg" style="width: 12%; text-align: right" title="Beginning balance">97,102</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziDwn3fOsDod" style="width: 12%; text-align: right" title="Beginning balance">33,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zL5s0aOjz5v1" style="width: 12%; text-align: right" title="Beginning balance">486,612</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Beginning balance"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accrual of warrant obligation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zhqiwhizuz3h" style="text-align: right" title="Accrual of warrant obligation">6,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIxb1BzOkyai" style="text-align: right" title="Accrual of warrant obligation"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFCN6OjzMbKa" style="text-align: right" title="Accrual of warrant obligation"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTcoBqjH8xS1" style="text-align: right" title="Accrual of warrant obligation">6,666</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Issuance of warrants and conversion option</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z1RWheuspwge" style="text-align: right" title="Issuance of warrants and conversion option">11,377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zSMPMeUnwOig" style="text-align: right" title="Issuance of warrants and conversion option"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC95RdqeCg33" style="text-align: right" title="Issuance of warrants and conversion option">5,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsAndConversionOption_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdH7YvkrYTKi" style="text-align: right" title="Issuance of warrants and conversion option">16,477</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Common stock issued in satisfaction of accrued compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCommonStockIssuedInSatisfactionOfAccruedCompensation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZZv9NyhMCh5" style="text-align: right" title="Common stock issued in satisfaction of accrued compensation"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCommonStockIssuedInSatisfactionOfAccruedCompensation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrEsXQOdWRwj" style="text-align: right" title="Common stock issued in satisfaction of accrued compensation">(45,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCommonStockIssuedInSatisfactionOfAccruedCompensation_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVB5XlsQBRZ3" style="text-align: right" title="Common stock issued in satisfaction of accrued compensation"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCommonStockIssuedInSatisfactionOfAccruedCompensation_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8JLiVHI87Di" style="text-align: right" title="Common stock issued in satisfaction of accrued compensation">(45,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNeXjwy03AO8" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(85,693</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z3GvBZTKEcO5" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(766</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zsFeoMibl4tf" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(5,800</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ztJiCflCbcke" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(92,259</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Change in fair value"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance - March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCKCSu9EMWvb" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">288,860</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zskyx4ty9ZKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">51,336</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--DerivativeLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVBPpr0MpFh2" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">32,300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7WmBEYOtXFb" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">372,496</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 216085 37348 581503 834936 7760 141397 144723 -2935 -34 -27675 -28889 220910 37314 695225 950770 356510 97102 33000 486612 6666 6666 11377 5100 16477 -45000 -45000 -85693 -766 -5800 -92259 288860 51336 32300 372496 <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zKR9ZOHBBBTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In applying the Black-Scholes option pricing model utilized in the valuation of Level 3 liabilities, the Company used the following approximate assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zeXgMVUp3XT" style="display: none">Schedule of Assumptions Used for Valuation of Level 3 Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zsWZO5KiAnji" title="Derivative liabilities , Risk-free interest rate">3.89</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zyZZ1wln30ka" title="Derivative liabilities , Risk-free interest rate">4.35</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zKZeCZXfkVy6" title="Derivative liabilities , Risk-free interest rate">3.84</span>% - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zJ3vOfEfJxw" title="Derivative liabilities , Risk-free interest rate">4.35</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zf43XxFj7TA7" title="Derivative liability, Expected term (years)">2.62</span> - <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zxj1NBib9WZc" title="Derivative liability, Expected term (years)">10.00</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zkJTvdu0dhC4" title="Derivative liability, Expected term (years)">3.58</span> - <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zf8wvajBtXp4" title="Derivative liability, Expected term (years)">5.00</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zJSH2cJYmpf" title="Derivative liability, Expected volatility">70</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zCkMG5kh2Fm3" title="Derivative liability, Expected volatility">65</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20250101__20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zCI7VtzQ5ebh" title="Derivative liability, Expected dividends">0.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zp7MQ0SAFmn9" title="Derivative liability, Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 0.0389 0.0435 0.0384 0.0435 P2Y7M13D P10Y P3Y6M29D P5Y 0.70 0.65 0.00 0.00 183095 183095 34788 34788 0.19 0.19 42930 42930 2526 2560 <p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zNbH3LN7SCl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_820_zyiVAuB3Wz95">Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2025 and through the date of this filing, notes and convertible notes payable with principal amounts totaling approximately $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20250331__us-gaap--DebtInstrumentAxis__custom--NotesAndConvertibleNotesPayableMember_zhSo1Jw0WZ49" title="Principal amounts">6,328,000</span> and $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20260511__us-gaap--DebtInstrumentAxis__custom--NotesAndConvertibleNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8WxnrtEGtni">11,116,000</span>, respectively, were past due. Such notes continue to accrue interest, and all relevant penalties have been accrued as of March 31, 2025. The Company is in negotiations with certain holders of notes payable to extend the maturity dates of such notes or to convert the principal and accrued interest into equity. As of March 31, 2025, the Company had an accrued interest balance of $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20250331__us-gaap--DebtInstrumentAxis__custom--NotesAndConvertibleNotesPayableMember_zWfRyVaQk4m7" title="Interest payable">1,432,967</span> related to notes and convertible notes payable that were past due.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025 and 2024, the Company recorded interest expense of $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--NotesAndConvertibleNotesPayableMember_zpN1VS087Hbj" title="Interest expense">427,237</span> and $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--NotesAndConvertibleNotesPayableMember_zRwHpmbnst5e" title="Interest expense">222,814</span>, respectively, and amortization of debt discount of $<span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--NotesAndConvertibleNotesPayableMember_z3GBliHXQjW6" title="Amortization of debt discount">86,637</span> and $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--NotesAndConvertibleNotesPayableMember_zmy5x1WQGXj2" title="Amortization of debt discount">5,956</span>, respectively. As of March 31, 2025 and December 31, 2024, the Company had $<span id="xdx_90E_eus-gaap--InterestPayableCurrent_iI_c20250331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zOL0Zl1au2g6" title="Accrued interest and penalties">3,362,097</span> and $<span id="xdx_90B_eus-gaap--InterestPayableCurrent_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_z8j9F1byCGy5" title="Accrued interest and penalties">2,967,854</span>, respectively, of accrued interest and penalties related to notes payable, which is included within accrued interest and accrued interest – related parties on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Notes Payable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company entered into a note amendment agreement with a note holder to (i) extend the maturity date of a note in the principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zmTHK5gfbPja" title="Principal amount">150,000</span> to the earlier of June 30, 2025 or the fifth day after the Company completes an Uplist Offering (as defined in the agreement) and (ii) waive any existing event of default under the note. Contemporaneous with the execution of this amendment, the Company issued to the lender an additional five-year warrant to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zfQHocLa12ad" title="Warrants purchase shares">200,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z2u5k63bEeY5" title="Exercise price">0.75</span> per share. This transaction was accounted for as a debt modification. The warrants had an issuance date fair value of $<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zDyjbUVFC2b9" title="Fair value of warrants">11,860</span> and were accounted for as derivative liabilities under the Company’s sequencing policy on the condensed consolidated balance sheet as of March 31, 2025. As of March 31, 2025, $<span id="xdx_907_eus-gaap--NotesPayable_iI_pid_c20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zHX7ARabMeR3" title="Outstanding principal balance">150,000</span> of principal remained outstanding under this note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Notes Payable - Related Parties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company received proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zYDViupFX6Me" title="Proceeds from investors">327,000</span> from an investor and issued a note payable in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20250331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zA5rQWRKeXyf" title="Principal amount">385,860</span> with a maturity date of <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zBcesuBrnBz" title="Maturity date">April 27, 2025</span>. The note bears interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zror87loTjF1" title="Interest rate">12</span>% per annum and has an original issue discount of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20250331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zveAjW9EGEOg" title="Original issue discount">58,860</span> which was recorded as a debt discount and will be amortized over the term of the note. In connection with the issuance, the Company issued <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zPGOrw0dB2S1" style="display: none" title="Warrants term">10</span>ten-year immediately vested warrants to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zzIYcqtlQjTl" title="Warrants purchase shares">490,500</span> shares of common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zgCsnCroZh8g" title="Exercise price">0.75</span> per share. The warrants had an issuance date fair value of $<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstanding_iI_pid_c20250331__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zZot68M1Xfki" title="Fair value of warrants">55,356</span> which was included within derivative liabilities - related parties, recorded as a debt discount and will be amortized over the term of the note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible Notes Payable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company received proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotePayableMember_zUA1KFssg0B5" title="Proceeds from related party">50,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from investors and issued notes payable in the aggregate principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z8dSMUZxzqR" title="Principal amount">66,080</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a maturity date of <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20250101__20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zqRMTjqfa5Z6" title="Maturity date">October 30, 2025</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The note bears interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zIw4dwO5ynQa" title="Bears interest rate">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% per annum and has an original issue discount of $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zAUSlK9xuhjc" title="Original issue discount">10,080</span> and incurred debt issuance costs of $<span id="xdx_90D_eus-gaap--DeferredFinanceCostsNet_iI_c20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zgqU8GYTCRv6" title="Debt issuance costs">6,000</span>, both of which were recorded as a debt discount and will be amortized over the term of the note. The note is convertible into shares of the Company’s common stock in the event of a default at a conversion price equal to <span id="xdx_904_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20250101__20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zIcm12lXsOoh" title="Trading price percentage">65</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the trading price of the Company’s common stock during the 20-trading day period prior to conversion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company entered into a note amendment agreement with a note holder to extend the maturity date of a convertible note in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementOneMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zv6ECjf7qE4f" title="Principal amount">50,000</span> <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDateDescription_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementOneMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zpkSVueFntQ3" title="Maturity date extension description">from December 23, 2024 to April 30, 2025</span>. The note currently accrues interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementOneMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__srt--RangeAxis__srt--MinimumMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zrdLj3qqIxt5" title="Interest rate">10</span>% per annum. If the note is not repaid in full by April 30, 2025, any further extension will require the issuance of an additional <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementOneMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z45BP6y3Y9Ce" style="display: none" title="Warrants term">5</span>five-year warrant to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementOneMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zht5FaAl22X8" title="Warrants to purchase shares">50,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementOneMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zupKChDuFND6" title="Exercise price">0.75</span> per share. Contemporaneous with the execution of this amendment, the Company issued to the lender an additional <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementOneMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z97VsepE8r91" style="display: none" title="Warrants term">5</span>five-year warrant to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementOneMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z2ccnJ8KqfWc" title="Warrants to purchase shares">150,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementOneMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zGvUWZde1CLc" title="Exercise price of shares">0.75</span> per share. This transaction was accounted for as a debt modification. The warrants had an issuance date fair value of $<span id="xdx_90B_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pp0p0_c20250331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementOneMember_zlWpG1DEGzlj" title="Fair value">8,915</span> and were accounted for as derivative liabilities under the Company’s sequencing policy on the condensed consolidated balance sheet as of March 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company entered into a note amendment agreement with a note holder to extend the maturity date of a convertible note in the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementTwoMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zBuVFzr8snzd" title="Principal amount">25,000</span> <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDateDescription_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementTwoMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z04XepENdWI6" title="Maturity date extension description">from December 26, 2024 to April 30, 2025</span>. The note currently accrues interest at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementTwoMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__srt--RangeAxis__srt--MinimumMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zM6RMRYCjnfe" title="Interest rate">10</span>% per annum. If the note is not repaid in full by April 30, 2025, any further extension will require the issuance of an additional <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementTwoMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zx384vxdCJ4i" style="display: none" title="Warrants term">5</span>five-year warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementTwoMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zR6atnvgUtah" title="Warrants to purchase shares">25,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementTwoMember__srt--TitleOfIndividualAxis__custom--NoteholderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z5KOvtw3JiMe" title="Exercise price">0.75</span> per share. Contemporaneous with the execution of this amendment, the Company issued to the lender an additional <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementTwoMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zXStsZrip28a" style="display: none" title="Warrants term">5</span>five-year warrant to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementTwoMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zytLO5UY3fzc" title="Warrants to purchase shares">75,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20250331__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementTwoMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zLnV9Bv6Imzf" title="Exercise price of shares">0.75</span> per share. This transaction was accounted for as a debt modification. The warrants had an issuance date fair value of $<span id="xdx_904_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pp0p0_c20250331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementTwoMember_zisdYmTJs1E9" title="Fair value">4,457</span> and were accounted for as derivative liabilities under the Company’s sequencing policy on the condensed consolidated balance sheet as of March 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company repaid an investor $<span id="xdx_901_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zRHTVf2y0wRd" title="Proceeds from investors">75,000</span> of principal on a past due convertible note. As of March 31, 2025, the outstanding principal balance of the note was $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20250331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z9eKXO2XUyUc" title="Outstanding principal balance">50,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 6328000 11116000 1432967 427237 222814 86637 5956 3362097 2967854 150000 200000 0.75 11860 150000 327000 385860 2025-04-27 0.12 58860 P10Y 490500 0.75 55356 50000 66080 2025-10-30 0.12 10080 6000 0.65 50000 from December 23, 2024 to April 30, 2025 0.10 P5Y 50000 0.75 P5Y 150000 0.75 8915 25000 from December 26, 2024 to April 30, 2025 0.10 P5Y 25000 0.75 P5Y 75000 0.75 4457 75000 50000 <p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLPKvj0IaJV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_822_zP6NCXC4FQoh">Stockholders’ Deficiency</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock Dividends</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025 and 2024, the Company accrued additional preferred dividends of $<span id="xdx_901_eus-gaap--DividendsPreferredStock_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zglhh0CLCXTb" title="Accrued additional preferred dividends">352,248</span> and $<span id="xdx_905_eus-gaap--DividendsPreferredStock_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zgv4wqDR7D74" title="Accrued additional preferred dividends">326,665</span>, respectively. As of March 31, 2025 and December 31, 2024, there were accrued preferred stock dividends payable of $<span id="xdx_900_eus-gaap--DividendsPayableCurrent_iI_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVw3pWWHwLIl" title="Accrued dividend payable">359,453</span> and $<span id="xdx_901_eus-gaap--DividendsPayableCurrent_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuSHJJo39MF3" title="Accrued dividend payable">7,205</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series B Convertible Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company received gross proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zhdAzRTGloWg" title="Proceeds from issuance of convertible preferred stock">25,000</span> from an investor in connection with the sale of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zbVgb7CRccO7" title="Common stock, shares">3,333</span> shares of its Series B Convertible Preferred Stock and issued <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zyDM8Yjjy01k" style="display: none" title="Warrants term">5</span>five-year warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z2QVWvYSHrHe" title="Warrants to purchase of common stock">37,500</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zJOXfr5K9jTc" title="Warrant exercise price">0.75</span> per share. The warrants and embedded conversion options were accounted for as derivative liabilities under the Company’s sequencing policy and had an aggregate issuance date fair value of $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zLWRCt7Swp41" title="Fair value of warrants">3,006</span>. Subsequent to March 31, 2025, the Company completed the issuance of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20260511__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znfUCVMH2VL3" title="Shares issued">3,333</span> shares of its Series B Convertible Preferred Stock. The proceeds related to the issuance were received during the three months ended March 31, 2025, and were recorded within additional paid-in capital on the condensed consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company received gross proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zGIoKlR8U3Pb" title="Proceeds from issuance of Common Stock">150,000</span> from an investor in connection with the sale of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zPrORstz6Fa" title="Common stock, shares">428,572</span> shares of its common stock and <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zsUAQSzvw4nk" style="display: none" title="Warrants term">10</span>ten-year warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zv1qNZHlBlPi" title="Warrants to purchase of common stock">428,572</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zWjgh4V2wlyh" title="Warrant exercise price">0.35</span> per share. The warrants had an issuance date fair value of $<span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zJWpkCc0fij1" title="Fair value of warrants">57,803</span> and were accounted for as derivative liabilities under the Company’s sequencing policy on the condensed consolidated balance sheet as of March 31, 2025. Subsequent to March 31, 2025, the Company completed the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20260511__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyiLfu3Djf04" title="Shares issued">428,572</span> shares of its Common Stock. The proceeds related to the issuance were received during the three months ended March 31, 2025, and were recorded within additional paid-in capital on the condensed consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company entered into an advisory agreement with a certain advisor to perform independent advisory services in connection with business operations from February 1, 2025 to June 30, 2025. In consideration of services to be performed, the Company will issue to the advisor <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhzbZpQsPBy7" title="Warrants term">5</span>-year warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNyAjF0SdSZk" title="Warrants to purchase common stock">150,000</span> shares of common stock, which vest <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAI4Q61TJ9hl" title="Warrant vesting percentage">20</span>% monthly during the term of the agreement at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNtI2D6mPJih" title="Exercise price">0.75</span> per share. The warrants had a grant date fair value of $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmySK6CfG1ag" title="Fair value of warrants">9,773</span> which will be recognized over the vesting term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2025, the Company entered into warrant amendment agreements with three advisory service providers to extend the expiration dates of warrants to purchase an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250331__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNcCiHQhIIwg" title="Warrants to purchase common stock">353,323</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGhLDhrO1Tk" title="Exercise price">0.75</span> per share. The original expiration dates ranged from February 2025 to June 2025 and were extended by <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250331__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPFTQh4yE70l" title="Warrants term">four years</span> to February 2029 to June 2029. All other terms of the warrants, including the exercise price, remained unchanged. The modifications were accounted for under ASC 718 and resulted in incremental stock-based compensation expense of $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zBQufLnBSwRg" title="stock-based compensation expense">17,200</span>, which was recognized immediately as the warrants were fully vested at the modification date, and was included within general and administrative expense on the condensed consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 5, <i>Notes Payable</i> for additional details associated with the issuance of stock warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Stock Options</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">During the three months ended March 31, 2025, the Company granted an aggregate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zu9Upj21gcC7" title="Stock options granted, shares">4,525,000</span> <span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zLFpYMrzsVI3" style="display: none" title="Vested term">5</span>five-year immediately vested options under the Company’s Equity Incentive Plan to three of the Company’s directors, the Chief Executive Officer, the Chairman of the Scientific Advisory Board and a consultant with an exercise price of $<span id="xdx_902_eus-gaap--StockOptionExercisePriceIncrease_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zGZ2znYrLga1" title="Exercise price">0.75</span> per share. The options had a grant date fair value of $<span id="xdx_90D_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20250101__20250331__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zJrCLhXvJxve" title="Stock options granted, value">100,600</span> which was recognized immediately, of which $<span id="xdx_902_eus-gaap--OtherGeneralAndAdministrativeExpense_c20250101__20250331_zCFrA6qwaJvk" title="General and administrative expense">67,200</span> was included within general and administrative expense and $<span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_c20250101__20250331_zebhfIgvdVhg" title="Research and development expense">33,400</span> was included within research and development expense on the condensed consolidated statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">During the three months ended March 31, 2025, the Company recognized stock-based compensation expense of $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20250101__20250331_zTVwyKeYerp7" title="Stock based compensation expense">104,475</span>, consisting of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zP1u1ZWe7Fe2" title="Warrants">3,875</span> of expense related to warrants (of which, $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpubqx8amOKc" title="Common stock, options and warrants">3,909</span> was included within stockholder’s deficiency and $(<span id="xdx_908_ecustom--AccruedCompensation_c20250101__20250331_z5tLxvqe0Cck" title="Accrued compensation">34</span>) was included within accrued compensation) and $<span id="xdx_90F_ecustom--ShareBasedCompensationIncludedInStockholdersDeficiency_pp0p0_c20250101__20250331__us-gaap--AwardTypeAxis__custom--ConsultingServicesMember_zcPni6SvUsU2" title="Stockholder's deficiency">100,600</span> related to options which was included within stockholders’ deficiency, of which $<span id="xdx_901_eus-gaap--OtherGeneralAndAdministrativeExpense_c20250101__20250331_zGS1AbspjM1a" title="General and administrative expense">67,200</span> was included within general and administrative expenses and $<span id="xdx_907_eus-gaap--OtherResearchAndDevelopmentExpense_c20250101__20250331_zWCTSe31Pbrf" title="Research and development expense">33,400</span> was included within research and development expenses on the condensed consolidated statement of operations. During the three months ended March 31, 2024, the Company recognized stock-based compensation expense of $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20240331_z1q4qKo261cg" title="Stock based compensation expense">288,895</span>, consisting of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0LT5KB52Nul" title="Warrants">26,544</span> of expense related to warrants (of which, $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTFUKFu3Rs57" title="Common stock, options and warrants">29,141</span> was included within stockholder’s deficiency and $(<span id="xdx_904_ecustom--AccruedCompensation_c20240101__20240331_zcbRBXSnD54" title="Accrued compensation">2,597</span>) was included within accrued compensation), and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ConsultingServicesMember_zVKfqlTd3101" title="Accrued compensation">262,351</span> of expense related to common stock issued or to be issued for consulting services (of which, $<span id="xdx_903_ecustom--ShareBasedCompensationIncludedInStockholdersDeficiency_pp0p0_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ConsultingServicesMember_zg4fIZb3WCFg" title="Stockholder's deficiency">260,520</span> was included within stockholder’s deficiency and $<span id="xdx_902_ecustom--AccruedCompensation_pp0p0_c20240101__20240331__us-gaap--AwardTypeAxis__custom--ConsultingServicesMember_zV3D5gPmplkk" title="Accrued compensation">1,831</span> was included within accrued compensation), which was included within general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">As of March 31, 2025, there was approximately $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20250331_zQSudgIFJAP" title="Unrecognized stock-based compensation expense">5,864</span> of unrecognized stock-based compensation expense related to unvested advisory warrants, which will be recognized over a weighted-average remaining period of approximately <span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331_z5S9Itj1bEp9" title="Weighted average remaining period">0.25</span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> 352248 326665 359453 7205 25000 3333 P5Y 37500 0.75 3006 3333 150000 428572 P10Y 428572 0.35 57803 428572 P5Y 150000 0.20 0.75 9773 353323 0.75 P4Y 17200 4525000 P5Y 0.75 100600 67200 33400 104475 3875 3909 34 100600 67200 33400 288895 26544 29141 2597 262351 260520 1831 5864 P0Y3M <p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zGJTxnjz7Jf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b>Note 7 – <span id="xdx_822_zq5h67up3Jh1">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">As of March 31, 2025 and December 31, 2024, the Company was required to issue warrants to purchase an aggregate of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250331__srt--TitleOfIndividualAxis__custom--FormerDirectorMember_z3MGb1z2KcD6" title="Warrants purchase for common stock">2,331,500</span> and <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__srt--TitleOfIndividualAxis__custom--FormerDirectorMember_zr2zKrT50Fe7" title="Warrants purchase for common stock">2,256,500</span>, respectively, shares of common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__srt--TitleOfIndividualAxis__custom--FormerDirectorMember_zjXym9QW4PG" title="Warrant exercise price per share"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--FormerDirectorMember_zL9gzI5qJdXk" title="Warrant exercise price per share">0.75</span></span> per share to former directors of the Company in connection with loans made to the Company in the aggregate amount of $<span id="xdx_908_eus-gaap--LoansPayable_iI_c20250331__srt--TitleOfIndividualAxis__custom--FormerDirectorMember_z6dtstOwLYUc" title="Loan amount">459,000</span> which required certain penalties be paid in the form of warrants. As a result, the Company accrued $<span id="xdx_90B_eus-gaap--LoansPayableFairValueDisclosure_iI_pp0p0_c20250331__srt--TitleOfIndividualAxis__custom--FormerDirectorMember_zdR7NpBtCAac" title="Fair value of loan obligations">131,792</span> and $<span id="xdx_90D_eus-gaap--LoansPayableFairValueDisclosure_iI_c20241231__srt--TitleOfIndividualAxis__custom--FormerDirectorMember_zZyg4Xwn3KPb" title="Fair value of loan obligations">129,113</span> associated with the fair value of the obligations as of March 31, 2025 and December 31, 2024, respectively, which amount is included in warrant liabilities – related parties on the condensed consolidated balance sheets. The obligations to issue warrants are subject to changes in fair value at each reporting period. See Note 4, <i>Fair Value</i> for additional details.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">See Note 5, <i>Notes Payable – Notes Payable – Related Parties</i> for details related to convertible notes held by directors of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> 2331500 2256500 0.75 0.75 459000 131792 129113 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zPpKHo2Lsb5g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b>Note 8 – <span id="xdx_822_zNS9LNTt5LSf">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Yeda Research and License Agreement</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">During the three months ended March 31, 2025 and 2024, the Company recorded research and development expenses of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--YedaResearchAndLicenseAgreementMember_ztjn4YkQHmVa" title="Research and development expenses"><span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--YedaResearchAndLicenseAgreementMember_z1pbt23WQPo3" title="Research and development expenses">14,500</span></span> related to its Research and License Agreement with Yeda (the “Agreement”). As of March 31, 2025 and December 31, 2024, the Company had $<span id="xdx_901_eus-gaap--AccruedLiabilitiesCurrent_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--YedaResearchAndLicenseAgreementMember_zuFyqnYeWbVk" title="Accrued research and development expenses">145,000</span> and $<span id="xdx_900_eus-gaap--AccruedLiabilitiesCurrent_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--YedaResearchAndLicenseAgreementMember_zo32vf59bNqh" title="Accrued research and development expenses">130,500</span>, respectively, of accrued research and development expenses pursuant to the Agreement with Yeda.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><b><i>MD Anderson Sponsored Research Agreements</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The Company recognized $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--MDAndersonAgreementsMember_zqsjAkqac2L1" title="Research and development expense">445,000</span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--MDAndersonAgreementsMember_zYP3rAuU3zM5" title="Research and development expense">324,000</span> of research and development expenses during the three months ended March 31, 2025 and 2024, respectively, associated with services provided by The University of Texas M.D. Anderson Cancer Center (“MD Anderson”) under the two agreements with MD Anderson dated November 2018 and February 2019, respectively. During the three months ended March 31, 2025, the Company executed Amendment No. 6 to the Sponsored Research Agreement, extending the term of the agreement by three months from February 28, 2025 through May 27, 2025, for an additional payment of $<span id="xdx_904_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20250228__20250527__us-gaap--TypeOfArrangementAxis__custom--MDAndersonAgreementsMember_zT8aqppJimKg" title="Additional payment">327,000</span> due upon execution. As of March 31, 2025 and December 31, 2024, the Company had $<span id="xdx_90A_ecustom--PrepaidExpensesResearchAndDevelopmentCurrent_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--MDAndersonAgreementsMember_zzbFmQ7KTJ9i" title="Prepaid research and development expenses">209,427</span> and $<span id="xdx_901_ecustom--PrepaidExpensesResearchAndDevelopmentCurrent_iI_dxL_c20241231__us-gaap--TypeOfArrangementAxis__custom--MDAndersonAgreementsMember_zHp4IomGH5sd" title="Prepaid research and development expenses::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1205">0</span></span>, respectively, of prepaid research and development expenses, $<span id="xdx_905_ecustom--AccruedResearchAndDevelopment_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--MDAndersonAgreementsMember_ziU8c6hje6Ql" title="Accrued research and development">343,544</span> and $<span id="xdx_909_ecustom--AccruedResearchAndDevelopment_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--MDAndersonAgreementsMember_znPOih0kbQ35" title="Accrued research and development">16,545</span> of accrued research and development expenses and $<span id="xdx_906_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20250331__us-gaap--TypeOfArrangementAxis__custom--MDAndersonAgreementsMember_zEFujod6OTAc" title="Accounts payable">1,114,372 </span>and $<span id="xdx_90D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20241231__us-gaap--TypeOfArrangementAxis__custom--MDAndersonAgreementsMember_zlQBJUpXYXmi" title="Accounts payable">1,189,372</span> of accounts payable, respectively, pursuant to the agreements with MD Anderson on the condensed consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Litigation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Loss contingencies considered remote are generally not disclosed, unless they involve guarantees, in which case the guarantees would be disclosed. There can be no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows. Aside from the matters discussed above, there are no other known contingencies through the date of this filing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b> </b></p> 14500 14500 145000 130500 445000 324000 327000 209427 343544 16545 1114372 1189372 <p id="xdx_802_eus-gaap--SegmentReportingDisclosureTextBlock_zELDZCSslsi9" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Note 9 – <span id="xdx_828_znyyLd5kn173">Segment Reporting</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The Company has <span id="xdx_90C_eus-gaap--NumberOfOperatingSegments_dc_uSegments_c20250101__20250331_zQ08gNloYpNf" title="Number of operating segments"><span id="xdx_904_eus-gaap--NumberOfReportableSegments_dc_uSegments_c20250101__20250331_zYuzFkeqHXQc" title="Number of reportable segments">one</span></span> operating and reporting segment, Cell Source, Inc., the development of proprietary immune system management technology. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker (“CODM”), who is the Company’s chief executive officer, utilizes the Company’s financial information on an aggregate, consolidated basis for purposes of making operating decisions, allocating resources and assessing financial performance, as well as for making strategic operations decisions and managing the organization. The CODM is not regularly provided with disaggregated actual expense information, other than the actual expense information included in the condensed consolidated statements of operations. The measure of segment assets is reported on the condensed consolidated balance sheet as total assets. The Company’s significant segment expenses are as presented in the Company’s condensed consolidated statement of operations. The Company has not yet generated any revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> 1 1 <p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_ztNO9nresy7a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b>Note 10 – <span id="xdx_820_zo3NTLB99nlg">Subsequent Events</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i>Issuance of Series B Convertible Preferred Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company received proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20250401__20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5LqAmvlnMF4" title="Gross proceeds from preferred stock">310,000</span> from investors in connection with the issuance of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9RIEdekhIKe" title="Shares issued">41,332</span> shares of its Series B Convertible Preferred Stock and <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLd3FqgGjlka" style="display: none" title="Warrants term">5</span>five-year warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRPZf5oDwq7a" title="Warrants to purchase shares">465,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zonNInODW5Wd" title="Warrants exercise price">0.75</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company completed the issuance of <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250401__20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKnAIKd56dLe" title="Debt conversion shares issued">3,333</span> shares of its Series B Convertible Preferred Stock. The proceeds related to the issuance were received during the three months ended March 31, 2025, and were recorded within additional paid-in capital on the condensed consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i>Issuance of Common Stock </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company received gross proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20250401__20260511__srt--TitleOfIndividualAxis__custom--IssuanceOfCommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOdSqU4lOFLb" title="Gross proceeds from preferred stock">100,000</span> from an investor in connection with the issuance of an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20260511__srt--TitleOfIndividualAxis__custom--IssuanceOfCommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zy4896rR3wRg" title="Shares issued">285,714</span> shares of its Common Stock and <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260511__srt--TitleOfIndividualAxis__custom--IssuanceOfCommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjsKaEgfNq49" style="display: none" title="Warrants term">10</span>ten-year warrants to purchase an aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260511__srt--TitleOfIndividualAxis__custom--IssuanceOfCommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2rONaWzajIj" title="Warrants to purchase shares">285,714</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260511__srt--TitleOfIndividualAxis__custom--IssuanceOfCommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxlOoH9VOzLk" title="Warrants exercise price">0.35</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company completed the issuance of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20260511__srt--TitleOfIndividualAxis__custom--IssuanceOfCommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztM5eDRf1iE6" title="Shares issued">428,572</span> shares of its Common Stock. The proceeds related to the issuance were received during the three months ended March 31, 2025, and were recorded within additional paid-in capital on the condensed consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company issued an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20260511__srt--TitleOfIndividualAxis__us-gaap--DeferredProfitSharingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEJaxINYs6Qe" title="Shares issued">1,282,270</span> shares of its common stock as payment-in-kind dividends to holders of its Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, and Series C Convertible Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i>Issuance of Notes Payable</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company received proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromNotesPayable_c20250401__20251115__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdB4fcOYOKDh" title="Proceeds from issuance of notes payable">50,000</span> from an investor and issued a note payable in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20251115__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5lhYbZ0uP4j" title="Principal amount">62,500</span> with a maturity date of November 15, 2025. The note has an original issue discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20261115__us-gaap--ShortTermDebtTypeAxis__custom--IssuanceOfNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFbJTXfx2pL7" title="Original issue discount">12,500</span>. In connection with the issuances, the Company issued a <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251115__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--IssuanceOfNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXnHAkdGSTO6" style="display: none" title="Warrants term">10</span>ten-year immediately vested warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251115__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--IssuanceOfNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zc2HtZxzh4q6" title="Number of warrants issued">75,000</span> shares of common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251115__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--IssuanceOfNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVvOoxtDjJM8" title="Warrants exercise price">0.35</span> per share. As of the date of these financial statements, this note was past due. See Note 2, <i>Going Concern</i>, and Note 5, <i>Notes Payable</i>, for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company received proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromNotesPayable_c20250401__20251116__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUItwlbkx71h" title="Proceeds from issuance of notes payable">30,000</span> from an investor and issued a note payable in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20251116__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNnOyGvw6gW7" title="Principal amount">37,500</span> with a maturity date of November 16, 2025. The note bears interest at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20251116__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUlxVMaQHBka" title="Debt instrument, interest rate">10</span>% per annum and has an original issue discount of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20251116__us-gaap--ShortTermDebtTypeAxis__custom--IssuanceOfNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMgJ8Jv73lOe" title="Original issue discount">7,500</span>. In connection with the issuances, the Company issued a <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251116__us-gaap--TypeOfArrangementAxis__custom--IssuanceOfNotesPayableMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWgXtDqM7wIi" style="display: none" title="Warrants term">10</span>ten-year immediately vested warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251116__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--TypeOfArrangementAxis__custom--IssuanceOfNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1Ldr0PcDas5" title="Number of warrants issued">45,000</span> shares of common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251116__us-gaap--TypeOfArrangementAxis__custom--IssuanceOfNotesPayableMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQdvBbdbxxfl" title="Warrants exercise price">0.35</span> per share. As of the date of these financial statements, this note was past due. See Note 2, <i>Going Concern</i>, and Note 5, <i>Notes Payable</i>, for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company received net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromNotesPayable_c20250401__20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCZ7KewanN74" title="Proceeds from issuance of notes payable">200,000</span> from an investor and issued a note payable in the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zULCQlzOSqKl" title="Principal amount">285,714</span> pursuant to a note purchase agreement which provides that the investor will loan an additional $<span id="xdx_90F_eus-gaap--LoansPayable_iI_c20260511__us-gaap--TypeOfArrangementAxis__custom--IssuanceOfNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z21OUPlhKh74" title="Loans payable">800,000</span> in seven tranches upon the occurrence of certain events, including the completion by the Company of certain filings with the Securities Exchange Commission. If all tranches are funded, the aggregate principal amount of the notes issued pursuant to the Note Purchase Agreement will be $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--PurchaseCommitmentExcludingLongtermCommitmentAxis__us-gaap--PurchaseCommitmentMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z32oUiZ5geVl" title="Principal amount">1,428,571</span>. The note is secured by substantially all of the assets of the Company and is convertible into shares of the Company’s common stock in the event of a default under the note at a conversion price equal to <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_dp_c20260511__us-gaap--TypeOfArrangementAxis__custom--IssuanceOfNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zK1hxBCqewQh" title="Conversion price percentage">65</span>% of the trading price of the Company’s common stock during the 20-trading day period prior to conversion. The notes will be due on February 24, 2026. The Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zeokx14ONfbe" title="Number of new stock issued">1,714,286</span> shares of common stock (the “Origination Shares”) and a warrant to purchase <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250401__20260511__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5f9tXx6b8H8" title="Warrant to purchase">571,429</span> shares of common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmEoJVkUFsxa" title="Warrants exercise price">0.25</span> per share to the investor pursuant to the terms of the note purchase agreement. If all tranches are funded, the Company will be required to issue warrants to purchase an additional <span id="xdx_90F_eus-gaap--StockholdersEquityOtherShares_c20250401__20260511__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyhHT7RwZ8sl" title="Other Shares">2,285,714</span> shares of common stock to the investor. The investor has been granted “piggyback” registration rights with respect to the Origination Shares and the shares issuable upon conversion of the notes and exercise of the warrants and rights to participate in future financings. The Company will be required to issue additional shares of common stock to the investor if the market value of the Origination Shares falls below $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueOther_c20250401__20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zR31ftoKglv6" title="Issue additional shares of common stock">428,571</span>. As of the date of these financial statements, this note was past due. See Note 2, <i>Going Concern</i>, and Note 5, <i>Notes Payable</i>, for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company received aggregate proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromNotesPayable_c20250401__20260107__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlshfhNg3zE" title="Proceeds from notes payable">400,000</span> from investors and issued notes payable in the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentIssuedPrincipal_c20250401__20260107__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--IssuanceOfNotesPayableMember_zRDbqLcenJvb" title="Principal amount">500,000</span> with a maturity date of January 7, 2026. The notes bear interest at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260107__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNwuM97MjXc3" title="Debt instrument, interest rate">10</span>% per annum and have an original issue discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260107__us-gaap--ShortTermDebtTypeAxis__custom--IssuanceOfNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuRBml6zeit4" title="Original issue discount">100,000</span>. In connection with the issuances, the Company issued ten-year immediately vested warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260107__us-gaap--TypeOfArrangementAxis__custom--IssuanceOfNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zV4iwZNDmtc4" title="Number of warrants issued">1,000,000</span> shares of common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260107__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSoBndK2LGck" title="Warrants exercise price">0.75</span> per share. In connection with the issuances, the Company issued an aggregate of <span id="xdx_902_eus-gaap--StockholdersEquityOtherShares_c20250401__20260107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0zDRildQqr3" title="Other Shares">400,000</span> shares of its common stock. As of the date of these financial statements, this note was past due. See Note 2, <i>Going Concern</i>, and Note 5, <i>Notes Payable</i>, for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company received proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromNotesPayable_c20250401__20251120__us-gaap--TypeOfArrangementAxis__custom--IssuanceOfNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAkms3wt3dOe" title="Proceeds from notes payable">9,251</span> from an investor and issued a note payable in the principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentIssuedPrincipal_c20250401__20251120__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--IssuanceOfNotesPayableMember_z4KhSPxApEdd" title="Principal amount">11,564</span> with a maturity date of November 20, 2025. The note bears interest at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20251120__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzHK9w5VAnGj" title="Debt instrument, interest rate">10</span>% per annum and has an original issue discount of $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20251120__us-gaap--ShortTermDebtTypeAxis__custom--IssuanceOfNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSUhGZTd7TFe" title="Original issue discount">2,313</span>. In connection with the issuances, the Company issued a <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBeOb1ior9H4" style="display: none" title="Warrants term">5</span>five-year immediately vested warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQCuiXoeBbgc" title="Number of warrants issued">20,000</span> shares of common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4upXU275hMl" title="Warrants exercise price">0.75</span> per share. As of the date of these financial statements, this note was past due. See Note 2, <i>Going Concern</i>, and Note 5, <i>Notes Payable</i>, for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company received proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromNotesPayable_c20250401__20260511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--IssuanceOfNotesPayableMember_z2fZaxfAQN54" title="Proceeds from notes payable">149,500</span> from a related party investor and issued a note payable in the principal amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentIssuedPrincipal_c20250401__20260511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--IssuanceOfNotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zVTpSzQvojCi" title="Principal amount">186,875</span> with a maturity date of <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20250401__20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zbmfgf0WaNc3" title="Maturity date">December 2, 2026</span>. The note bears interest at <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zb9QXUM0lMs" title="Debt instrument, interest rate">10</span>% per annum and has an original issue discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__custom--IssuanceOfNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNX0XRUPL7j" title="Original issue discount">37,375</span>. In connection with the issuances, the Company issued a <span style="display: none"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zEd2aJv0Acw9" title="Warrants term">10</span></span>ten-year immediately vested warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zFGJrNMX1tl1" title="Number of warrants issued">373,750</span> shares of common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zgGX9ePTKEte" title="Warrants exercise price">0.75</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company completed a private placement of original issue discount convertible notes payable in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentIssuedPrincipal_c20250401__20260511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--PrivatePlacementConvertibleNotesPayableMember_ztwM4vqZZ4th" title="Principal amount">1,875,000</span>. The Company received net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20250401__20260511__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zruZmsoDlZdb" title="Proceeds from offering">1,500,000</span> from the offering. <span id="xdx_908_eus-gaap--SubsequentEventDescription_c20250401__20260511__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqaSbAstsvmb" title="Subsequent event, description">The notes bear interest at a rate of 10% per annum and are convertible into shares of the Company’s common stock at a conversion price equal to 90% of the lowest volume weighted average price of the common stock during the ten trading days prior to conversion.</span> The notes become due upon the earlier of June 17, 2026 or the listing of the Company’s common stock on the Nasdaq Capital Market or another national securities exchange. For each $<span id="xdx_90D_eus-gaap--ProceedsFromNotesPayable_c20250401__20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFyNddzehnB6" title="Proceeds from notes payable">100,000</span> invested, investors in the offering received a <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZQK6aCVCAZ2" style="display: none" title="Warrants term">5</span>five-year warrant to purchase the Company’s common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7e0blTnwcY2" title="Warrants exercise price">0.40</span> per share. A total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZY5tESO6k6c" title="Number of warrants issued">1,875,000</span> warrants were issued in the offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company received aggregate proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromNotesPayable_c20250401__20260511__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zc2Fmq2lt6m9" title="Proceeds from notes payable">450,000</span> from investors and issued notes payable in the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentIssuedPrincipal_c20250401__20260511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z1HmzMrzarW9" title="Principal amount">562,500</span> with maturity dates ranging from July 29, 2026 to <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_c20250401__20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z34icbrqP723" title="Maturity date">August 27, 2026</span>. The notes bear interest at <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsea9fYUavod" title="Debt interest rate">10</span>% per annum and have an original issue discount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__custom--IssuanceOfNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSWz4gTGR4hf" title="Original issue discount">112,500</span>. In connection with the issuances, the Company issued <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJXSEY94uJGe" style="display: none" title="Warrants term">5</span>five-year immediately vested warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPWYYIIvNuWg" title="Number of warrants issued">562,500</span> shares of common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyq1u2QoTs4" title="Warrants exercise price">0.40</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, a note payable to a lender in the original principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20260306__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEeOCV9b1ohj" title="Principal amount">202,500</span>, which matured on March 6, 2025 was satisfied in full. In connection with the satisfaction, the Company paid $<span id="xdx_90A_eus-gaap--RepaymentsOfNotesPayable_c20250401__20260306__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhKMCrvJNi5c" title="Paid remaining balance">100,000</span> and the remaining balance was paid by a third-party lender. Contemporaneous with the repayment, the Company entered into a business loan and security agreement with the third-party lender in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20260306__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjhYSop9H3I1" title="Principal amount">250,000</span> with a maturity date of <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_c20250401__20260306__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHtkxpznW1n1" title="Maturity date">May 11, 2026</span>. If the loan is not repaid by the maturity date, a late fee of 45% of the principal balance will be imposed. The loan is secured by substantially all of the assets of the Company and is personally guaranteed by a member of the Company’s Board of Directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to March 31, 2025, the Company received proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromNotesPayable_c20250401__20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z0O3ZBcXxux5" title="Proceeds from notes payable">50,000</span> from an investor and issued a convertible note payable in the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zjgSMqtzLQLh" title="Principal amount">62,500</span>. The note bears interest at a rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20260511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zqi49ovjTNy8" title="Bears interest rate">10</span>% per annum and has an original issue discount of $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyXfH5cXCOei" title="Original issue discount">12,500</span>. The note is convertible into shares of the Company’s common stock at a conversion price equal to 90% of the lowest volume weighted average price of the common stock during the ten trading days prior to conversion. The note becomes due upon the earlier of November 7, 2026 or the listing of the Company’s common stock on the Nasdaq Capital Market or another national securities exchange. In connection with the issuance, the Company issued a <span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCDYRwr4J6U" title="Warrants term">5</span></span>five-year immediately vested warrant to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYgscieRMhIb" title="Warrant to purchase common stock">62,500</span> shares of common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260511__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsFU1ieQBL2" title="Exercise price per share">0.40</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i>Note Amendments</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company entered into a note amendment agreement with a note holder to extend the maturity date of a note in the principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20250731__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1q1eFSomaZ8" title="Principal amount">50,000</span> from April 30, 2025 to July 31, 2025. If the note is not repaid in full by July 31, 2025, any further extension will require the issuance of an additional five<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260511__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1zpfdEeEXQ" style="display: none" title="Warrants term">5</span>-year warrant to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250731__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zy2OC7fLQthe" title="Warrants to purchase shares">50,000</span> shares of the Company’s common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250731__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0dIjifo9LR">0.75</span> per share. Contemporaneous with the execution of this amendment, the Company issued to the lender an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250731__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zUY3CHLUUgu8" style="display: none">5</span>five-year warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250731__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIwtLVGAg3Vf" title="Number of warrants issued">150,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250731__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zolWtOvZMoy6" title="Warrants exercise price">0.75</span> per share. This note was then amended again to extend the maturity date of the note from July 31, 2025 to December 31, 2025. Contemporaneous with the execution of this additional amendment, the Company issued to the lender an additional <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQbeSjnqOazd" style="display: none" title="Warrants term">5</span>five-year warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zF3ATvGE83fi" title="Number of warrants issued">200,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ7Z3zIlvKif" title="Warrants exercise price">0.75</span> per share. This note was then amended again to extend the maturity date of the note from December 31, 2025, to June 30, 2026. Contemporaneous with the execution of this additional amendment, the Company issued to the lender an additional five<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziGw7eha8bu7" style="display: none">5</span>-year warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260630__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zurjU5OROSD3" title="Number of warrants issued">300,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zWeUsQDQ2Rd5" title="Warrants exercise price">0.75</span> per share. In relation to this note, the Company issued to the lender an additional five-year warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260511__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember_zuCTvupCpFvk" title="Number of warrants issued">75,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember_zZPJ4RZXfAI5" title="Warrants exercise price">0.75</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company entered into a note amendment agreement with a note holder to extend the maturity date of a note in the principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20250731__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zt0Qxe4ijkr7" title="Principal amount">25,000</span> from April 30, 2025 to July 31, 2025. If the note is not repaid in full by July 31, 2025, any further extension will require the issuance of an additional <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250731__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdayIOP10wxf" style="display: none" title="Warrants term">5</span>five-year warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250731__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zR1RO4SqFB3i" title="Number of warrants issued">25,000</span> shares of the Company’s common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250731__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYvAcZ1Rale">0.75</span> per share. Contemporaneous with the execution of this amendment, the Company issued to the lender an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250731__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0P9mPtJLinb" style="display: none">5</span>five-year warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250731__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUOKPYWfFspd" title="Number of warrants issued">75,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250731__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znV90tzKJgX7" title="Warrants exercise price">0.75</span> per share. This note was then amended again to extend the maturity date of the note from July 31, 2025 to December 31, 2025. Contemporaneous with the execution of this additional amendment, the Company issued to the lender an additional <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zD0YEWxNGwg7" style="display: none" title="Warrants term">5</span>five-year warrant to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znrqDeEmySFi" title="Warrants to purchase shares">100,000</span> shares of the Company’s common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbfZD6g16MU5" title="Warrants exercise price">0.75</span> per share. This note was then amended again to extend the maturity date of the note from December 31, 2025, to June 30, 2026. Contemporaneous with the execution of this additional amendment, the Company issued to the lender an additional five-year warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260630__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zaojKrNtZgw2" title="Number of warrants issued">150,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zFKWt7imsy55" title="Warrants exercise price">0.75</span> per share. In relation to this note, the Company issued to the lender an additional five-year warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260511__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuJXA8cXtNC1" title="Number of warrants issued">37,500</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--LenderMember_zT2MmucOgJKg" title="Warrants exercise price">0.75</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company entered into a note amendment agreement with a note holder to extend the maturity date of a convertible note in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__srt--TitleOfIndividualAxis__custom--HolderMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbz5hPzQTE5d" title="Principal amount">25,000</span> to December 31, 2025. Contemporaneous with the execution of this amendment, the Company issued to the lender an additional <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__srt--TitleOfIndividualAxis__custom--HolderMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWmrcdLkLjnc" style="display: none" title="Warrants term">5</span>five-year warrant to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__custom--HolderMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrxbfMAAOXn9" title="Number of warrants issued">75,000</span> shares of the Company’s common stock at an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__srt--TitleOfIndividualAxis__custom--HolderMember__us-gaap--TypeOfArrangementAxis__custom--NoteAmendmentAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKlGCykXsQNe" title="Warrants exercise price">0.75</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i>Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company entered into an amendment with certain option holders to extend the expiration date by four years from August 19, 2025 to August 19, 2029.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company entered into an option amendment with its CEO to extend the expiration date by five years from March 7, 2026 to March 7, 2031.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i>Stock Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company entered into warrant amendment agreements with certain investors to extend the expiration dates ranging from August 2025 to December 2025, to August 2029 to December 2030.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company entered into warrant amendment agreements with a related party investor to extend the expiration date of the warrants from June 18, 2025 to June 18, 2030, and March 2, 2026 to March 2, 2031. Contemporaneous with the execution of these amendments, the warrants have been assigned to the Darlene Soave Revocable Trust.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company entered into warrant amendment agreements with certain investors to extend the expiration dates from January 13, 2026 to January 13, 2030.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company entered into a warrant agreement with an investor to issue <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260511__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zo02mfeL2fvd" style="display: none" title="Warrants term">5</span>five-year warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260511__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfHrJPqYJUB2" title="Number of warrants issued">25,000</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260511__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO6yUIxjwnb6" title="Warrants exercise price">0.75</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the Company entered into an advisory agreement with a certain advisor to perform independent advisory services in connection with business operations from April 15, 2026 to July 15, 2026. In consideration of services to be performed, the Company shall issue to the advisor <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260511__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAD9u50uL785" title="Warrants term">5</span>-year warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260511__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3dwjr0ENq55" title="Warrants to purchase common stock">120,000</span> shares of common stock, which vest <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20250401__20260511__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlVe9fNafpr9" title="Warrant vesting percentage">33</span>% monthly during the term of the agreement at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260511__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSKOg0OXXef2" title="Exercise price">0.75 </span>per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i>Automatic Conversion of Preferred Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20260511__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFHIj8hSYdYa" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20260511__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvcTpwoRsi9a" title="Preferred stock, shares outstanding">1,342,195</span></span> issued and outstanding shares of the Company’s Series A Preferred Stock converted into <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20250401__20260511__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbHTSp7bZ03g" title="Shares issued upon stock conversion, shares">13,421,950</span> shares of the Company’s common stock in accordance with the terms of the Certificate of Designation governing the terms of the Series A Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Subsequent to March 31, 2025, the <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20260511__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0fsHZrRbxth" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20260511__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRSaXvozpdZc" title="Preferred stock, shares outstanding">537,482</span></span> issued and outstanding shares of the Company’s Series C Preferred Stock converted into <span id="xdx_900_eus-gaap--ConversionOfStockSharesIssued1_c20250401__20260511__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrpeYINNuj1a" title="Shares issued upon stock conversion, shares">5,374,820</span> shares of the Company’s common stock in accordance with the terms of the Certificate of Designation governing the terms of the Series C Preferred Stock.</p> 310000 41332 P5Y 465000 0.75 3333 100000 285714 P10Y 285714 0.35 428572 1282270 50000 62500 12500 P10Y 75000 0.35 30000 37500 0.10 7500 P10Y 45000 0.35 200000 285714 800000 1428571 0.65 1714286 571429 0.25 2285714 428571 400000 500000 0.10 100000 1000000 0.75 400000 9251 11564 0.10 2313 P5Y 20000 0.75 149500 186875 2026-12-02 0.10 37375 P10Y 373750 0.75 1875000 1500000 The notes bear interest at a rate of 10% per annum and are convertible into shares of the Company’s common stock at a conversion price equal to 90% of the lowest volume weighted average price of the common stock during the ten trading days prior to conversion. 100000 P5Y 0.40 1875000 450000 562500 2026-08-27 0.10 112500 P5Y 562500 0.40 202500 100000 250000 2026-05-11 50000 62500 0.10 12500 P5Y 62500 0.40 50000 P5Y 50000 0.75 P5Y 150000 0.75 P5Y 200000 0.75 P5Y 300000 0.75 75000 0.75 25000 P5Y 25000 0.75 P5Y 75000 0.75 P5Y 100000 0.75 150000 0.75 37500 0.75 25000 P5Y 75000 0.75 P5Y 25000 0.75 P5Y 120000 0.33 0.75 1342195 1342195 13421950 537482 537482 5374820 Convertible notes are assumed to be converted at the rate of $0.75 per common share, which is the conversion price as of March 31, 2025 and 2024. However, such conversion rates are subject to adjustment under certain circumstances, such as stock splits and stock dividends, which may result in the issuance of common shares greater than the amount indicated.